The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma ...

Checkpoint Therapeutics (CKPT) announced that the U.S. FDA has approved unloxcyt for the treatment of adults with metastatic cutaneous squamous ...

ESPN analyst Randy Moss, who retired from the NFL in 2012 after 14 seasons, revealed that he is a “cancer survivor” and will ...